Plus Therapeutics, Inc.

Plus Therapeutics, Inc. reported a net loss of $22.4 million for fiscal year 2025, driven by an operating loss of $15.3 million. Revenue of $5.2 million was derived entirely from the CPRIT grant supporting the development of rhenium (186 Re) obisbemeda for leptomeningeal metastases. Operating expenses totaled $20.5 million, with research and development at $8.4 million and general and administrative at $12.1 million. The company's cash position improved, with a net increase in cash and cash equivalents of $8.7 million, ending the period with $8.6 million in cash, cash equivalents, and restricted cash, primarily due to $30.3 million in net cash provided by financing activities. Management notes substantial doubt about the company's ability to continue as a going concern due to accumulated deficits and ongoing cash needs.

Key Takeaways